BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
Retrieved on:
Thursday, November 16, 2023
Clinical Trials, Cardiology, Energy, Nuclear, Radiology, Health, Pharmaceutical, General Health, Oncology, BWX Technologies, NYSE, GMP, Security (finance), Good manufacturing practice, Form 10-K, Investment, BWXT, Tat, Doctor of Philosophy, Actinium, PSMA, Annual report, Automation, Cancer, Actinium-225, Risk, Pharmaceutical industry, Fusion
Under the agreement, BWXT Medical (a subsidiary of BWX Technologies, Inc. (NYSE: BWXT)), will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology (actinium-227-free), enabling Fusion to produce actinium-225 at its Good Manufacturing Practice (GMP) manufacturing facility for the benefit of its clinical trials.
Key Points:
- Under the agreement, BWXT Medical (a subsidiary of BWX Technologies, Inc. (NYSE: BWXT)), will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology (actinium-227-free), enabling Fusion to produce actinium-225 at its Good Manufacturing Practice (GMP) manufacturing facility for the benefit of its clinical trials.
- BWXT’s proprietary generator technology allows for the on-demand isolation of high purity actinium-225 from the radium supplied by BWXT Medical.
- BWXT Medical’s innovative actinium-225 generator technology will have significant benefits for both clinical and future commercial supply.
- Under that agreement, BWXT Medical has been providing predetermined amounts of Fusion's actinium supply needs at volume-based pricing.